NLS Pharmaceutics (NASDAQ:NCEL) Shares Climb 3.5% – Should You Buy?

Shares of NLS Pharmaceutics Ltd. (NASDAQ:NCEL) traded up 3.5% during trading on Tuesday. The stock traded as high as $3.20 and last traded at $2.96. Approximately 7,212 shares traded hands during mid-day trading, an increase of 35% from the average session volume of 5,342 shares. The stock had previously closed at $2.86.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NCEL. Weiss Ratings raised shares of NLS Pharmaceutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 18th. Laidlaw started coverage on shares of NLS Pharmaceutics in a research note on Monday, July 13th. They issued a “buy” rating and a $23.00 price objective on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $23.00.

NLS Pharmaceutics Price Performance

The firm has a 50 day moving average of $3.25 and a two-hundred day moving average of $3.26.

NLS Pharmaceutics (NASDAQ:NCEL) last released its earnings results on Friday, September 18th. The company reported ($0.48) earnings per share (EPS) for the quarter.

About NLS Pharmaceutics

NLS Pharmaceutics AG is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly sleep-related conditions. The company’s research is based on the role of orexin, a neurotransmitter involved in regulating wakefulness, arousal and energy balance.

NLS Pharmaceutics has developed a portfolio of small-molecule orexin receptor agonists, including AAZ-A-154 and AAZ-A-172. These investigational compounds are intended to address disorders associated with excessive daytime sleepiness and impaired wakefulness, including narcolepsy and other neurological conditions.